Efficacy and safety of narlumosbart, an anti-RANKL monoclonal antibody, in postmenopausal women with osteoporosis: a multi-center, randomized, double-blind, placebo- and active-controlled, phased II studyResearch in context

Summary: Background: This study aimed to preliminarily explore the efficacy and safety of narlumosbart, an anti-RANKL monoclonal antibody, in treating postmenopausal women with osteoporosis. Methods: This multi-center, randomized, double -blind, placebo- and active-controlled study was conducted at...

Full description

Bibliographic Details

Published in:	EClinicalMedicine
Main Authors:	Yue Chi, Yukun Li, Qun Cheng, Hanqing Cai, Yuhong Zeng, Hui Sheng, Bing Song, Hongmei Li, Lin Shen, Min Li, Ying Xing, Mei Cheng, Yujin Ma, Difei Wang, Mei Zhu, Weiping Lu, Shuang Yan, Xueyuan Zhang, Jing Yuan, Baofang Yang, Jun Li, Juan Wang, Zhufeng Wu, Weibo Xia
Format:	Article
Language:	English
Published:	Elsevier 2025-07-01
Subjects:	Narlumosbart Postmenopausal osteoporosis Bone mineral density Bone turnover markers Adverse events
Online Access:	http://www.sciencedirect.com/science/article/pii/S2589537025002615